{
    "2018-09-06": [
        [
            {
                "time": "2018-09-06",
                "original_text": "【太平洋证券今日早读】医药行业深度报告|智飞生物、隆基股份公司点评|电子、计算机行业追踪20180906",
                "features": {
                    "keywords": [
                        "医药行业",
                        "智飞生物",
                        "隆基股份",
                        "电子",
                        "计算机"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "电子",
                        "计算机"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-06",
                "original_text": "【医药|杜佐远团队太平洋证券】智飞生物(300122)：EC诊断报产受理，联合微卡构建最强肺结核诊疗体系",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "EC诊断",
                        "微卡",
                        "肺结核",
                        "诊疗体系"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}